Stock Soars as Lilly’s New Pill Impresses in Early Trials

United States: On April 17, Eli Lilly experienced a stock surge because of its announcement about a new experimental pill, which showed an 8% weight reduction at specific dosage levels while also controlling blood sugar in study volunteers.

Eli Lilly published its research on orforglipron at its headquarters in Indianapolis through a news release on April 17. The pharmaceutical company specializes in selling weight loss drugs Mounjaro and Zepbound from its Indianapolis base, as reported by USA Today.

“We are pleased to see that our latest incretin medicine meets our expectations for safety and tolerability, glucose control, and weight loss, and we look forward to additional data readouts later this year,” said David A. Ricks, Lilly’s chair and CEO.

Ricks claims that if approved, the once-daily medication orforglipron could be “readily manufactured and launched at scale for use by people around the world.”

Eli Lilly stock booms on April 17

Lilly’s stocks rose 16% since 1 p.m. ET when they disclosed the results of their latest trial.

Lilly has developed a new medicine that serves what function?

Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trialshttps://t.co/bU8RK1kTFx pic.twitter.com/TOfKEzE9E7
— Forbes (@Forbes) April 17, 2025

Lilly announced the new pill would advance its “mission to decrease chronic diseases like type 2 diabetes” since it predicts 760 million adults will be affected by 2050.

Tests show the pill caused patient A1C values to decrease by 1.3% to 1.6% compared to a starting level of 8.0%, according to Lilly. The highest dose of the new medication orforglipron resulted in A1C levels below 6.5% in patients, which exceeds the standards set by the American Diabetes Association (ADA).

According to the Cleveland Clinic a typical A1C value in non-diabetic people remains below 5.7 percent. The medical community defines prediabetic A1C results as ranging between 5.7% and 6.4%, according to the medical literature.

Based on data from Lilly, subjects who received the maximum amount of the new drug experienced weight reduction averaging 16 pounds. Participants showed additional weight reduction potential after the trial period, according to Lilly, because their weight reduction had not reached a plateau.

When can the public access Lilly’s new medication pill?

More clinical testing and FDA approval processes stand in the way of Lilly releasing its new pill for public access.

Only the first of seven Phase 3 studies, according to Ricks, is “examining the safety and efficacy of orforglipron across people with diabetes and obesity.”

GLP-1s didn't become popular until scientists figured out how to extend the half-life for weekly instead of daily injections. People hate needles!

Eli Lilly just showed phase-3 results for a daily weight loss pill that's a bit over 50% as effective as Ozempic.

Stock's up 15%: pic.twitter.com/KdranVmBvJ
— Crémieux (@cremieuxrecueil) April 17, 2025

Adverse effects of Lilly’s new pill

Lilly recorded side effects related to its new medication at standard levels for GLP-1s which serve the primary treatment purpose for type 2 diabetes.

The main side effects reported to Lilly involved gastrointestinal issues which stayed within moderate-to-mild levels of severity. The trial showed that administering 3 mg, 12 mg, or 36 mg resulted in different side effect probability rates, including diarrhea (19%, 21% and 26%) and nausea (13%, 18% and 16%) as well as dyspepsia (10%, 20% and 15%) and constipation (8%, 17% and 14%) and vomiting (5%, 7% and 14%).

“With some concern of elevated rates of nausea and vomiting heading into today’s readout, these result firmly validate the tolerable profile of orforglipron,” BMO Capital Markets analyst Evan Seigerman said, per Reuters.

The trial research did not uncover any signs that suggested harm to the liver system according to Lilly’s report.

How would people take Lilly’s new pill?

The drug testing data demonstrates that Lilly’s new pill permits unrestricted food consumption and any timing within daily hours for intake without limitation within determined periods.